IP Library › Granted Patent US 12708658
Granted Patent B2
US 12708658 · App. 18/784,736 · Granted Aug 18, 2026

Compositions and methods for treating heart failure

Inventor: Mingdong Zhou (Shanghai, CN)
Assignee: Zensun (Shanghai) Science & Technology, Co., Ltd.
A61K38/1883A61K9/0019A61K45/06C07K14/4756G01N33/6893G01N33/74G01N2333/58G01N2800/325G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12708658
App. No.
18/784,736
Granted
Aug 18, 2026
Kind
B2
Abstract

The present invention provides methods for treating chronic heart failure patients using the medication comprising neuregulin. The methods comprise first performing a companion diagnostic test of each patient before treatment; and then providing a suitable treatment to the patient according to the results of the companion diagnostic test. When the result of the test is within a favorite treatment zone, the patient is suitable for heart failure treatment by administering an effective amount of neuregulin.

Claims (8)

1 . A method of treating a heart failure patient by neuregulin 1, the method comprising administering neuregulin 1 at an amount of 0.6 or 1.2 ug/kg to the heart failure patient; wherein the patient has been identified for treatment by neuregulin 1 based on a companion diagnostic test; wherein the neuregulin 1 comprises the amino acid sequence of SEQ ID NO: 1.

2 . The method of claim 1 , wherein the companion diagnostic test measures the plasma level of NT-proBNP in the patient.

3 . The method of claim 2 , wherein the result of the test is indicative for the treatment by neuregulin 1 when the plasma level of NT-proBNP≤4000 fmol/ml.

4 . The method of claim 2 , wherein the result of the test is indicative for the treatment by neuregulin 1 when the plasma level of NT-proBNP is between 1600 fmol/ml and 4000 fmol/ml.

5 . The method of claim 2 , wherein the result of the test is indicative for the treatment by neuregulin 1 when the plasma level of NT-proBNP is ≤1600 fmol/ml.

6 . The method of claim 2 , wherein the plasma level is measured by immunoassay.

7 . The method of claim 1 , wherein the companion diagnostic test is evaluating heart function by NYHA heart function classification.

8 . The method of claim 2 , wherein the result of the test is indicative for the treatment by neuregulin 1 when the heart function is NYHA class II or III.